Cabio Biotech Wuhan Co Ltd Market Cap ($188.66 Million)
Market Cap & Net Worth: Cabio Biotech Wuhan Co Ltd (688089)
Cabio Biotech Wuhan Co Ltd market cap. Cabio Biotech Wuhan Co Ltd (SHG:688089) has a market capitalization of $188.66 Million (CN¥1.29 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #16510 globally and #4629 in its home market, demonstrating a -2.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cabio Biotech Wuhan Co Ltd's stock price CN¥7.66 by its total outstanding shares 168309120 (168.31 Million). Also see Cabio Biotech Wuhan Co Ltd (688089) cash conversion ratio for how efficiently the company converts equity into cash flow.
Cabio Biotech Wuhan Co Ltd Market Cap History (2019–2026)
Cabio Biotech Wuhan Co Ltd market cap history from 2019 to 2026. Data shows change from $628.59 Million to $188.66 Million (-18.62% CAGR). Check Cabio Biotech Wuhan Co Ltd (688089) stock price for real-time trading data and today's change.
Cabio Biotech Wuhan Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cabio Biotech Wuhan Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Cabio Biotech Wuhan Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.84x
Cabio Biotech Wuhan Co Ltd's market cap is 0.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.77x
Cabio Biotech Wuhan Co Ltd's market cap is 3.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $628.59 Million | $311.55 Million | $118.17 Million | 2.02x | 5.32x |
| 2020 | $675.34 Million | $323.46 Million | $130.59 Million | 2.09x | 5.17x |
| 2021 | $1.06 Billion | $351.11 Million | $128.58 Million | 3.01x | 8.21x |
| 2022 | $785.73 Million | $433.42 Million | $64.37 Million | 1.81x | 12.21x |
| 2023 | $440.86 Million | $443.80 Million | $91.37 Million | 0.99x | 4.82x |
| 2024 | $468.69 Million | $555.59 Million | $124.21 Million | 0.84x | 3.77x |
Competitor Companies of 688089 by Market Capitalization
Companies near Cabio Biotech Wuhan Co Ltd in the global market cap rankings as of November 8, 2026. Also see how large is Cabio Biotech Wuhan Co Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Cabio Biotech Wuhan Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Cabio Biotech Wuhan Co Ltd (2019–2026)
Market capitalization of Cabio Biotech Wuhan Co Ltd from 2019 to today. Between 2019 and today, Cabio Biotech Wuhan Co Ltd's market cap moved from $628.59 Million to $ 188.66 Million, with a yearly change of -18.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥188.66 Million | -67.10% |
| 2025 | CN¥573.36 Million | +22.33% |
| 2024 | CN¥468.69 Million | +6.31% |
| 2023 | CN¥440.86 Million | -43.89% |
| 2022 | CN¥785.73 Million | -25.55% |
| 2021 | CN¥1.06 Billion | +56.28% |
| 2020 | CN¥675.34 Million | +7.44% |
| 2019 | CN¥628.59 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Cabio Biotech Wuhan Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $188.66 Million USD |
| MoneyControl | $188.66 Million USD |
| MarketWatch | $188.66 Million USD |
| marketcap.company | $188.66 Million USD |
| Reuters | $188.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.